Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatment

Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatment

ESR1 mutation (ESR1m) is a frequent cause of acquired resistance to aromatase inhibitor (AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy for hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (...

Fuld beskrivelse

Saved in:
Bibliografiske detaljer
Main Authors: Nicholas C. Turner, Cynthia Huang Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, X. Cynthia, Erica L. Mayer, Yeon Hee Park, Stephen B. Fox, Xiaochun Liu, Sasha McClain, François‐Clément Bidard
Format: Artigo
Sprog:engelsk
Udgivet: 2023
Online adgang:https://doi.org/10.2217/fon-2022-1196
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Internet

https://doi.org/10.2217/fon-2022-1196

Lignende værker